MedTrace Logo

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

NCT00475956 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-04-15

No results posted yet for this study

Summary

The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.

Conditions

  • Neoplasms

Interventions

DRUG

AZD2171

oral tablet multiple ascending doses 20, 30 or 45 mg

DRUG

AZD0530

oral tablet multiple ascending doses 125 mg or 175 mg

Sponsors & Collaborators

Principal Investigators

  • Jane Roberston · AstraZeneca

  • Tanja Trarbach, MD · Universitatsklinikum der GHS Essen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-10-31
Completion
2009-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00475956 on ClinicalTrials.gov